Novavax and Serum Institute filed for Emergency Use Authorization of Novavax’ COVID-19 vaccine in South Africa
On Jan. 10, 2022, Novavax and Serum Institute of India announced a regulatory submission to the South African…
On Jan. 10, 2022, Novavax and Serum Institute of India announced a regulatory submission to the South African…
On Jan. 10, 2022, in a first-of-its-kind surgery, a 57-year-old patient with terminal heart disease received a successful…
On Dec. 28, 2021, Novavax and Serum Institute of India announced that the Drugs Controller General of India…
On Dec. 28, 2021, researchers at the Walter Reed Army Institute of Research in Silver Spring, Maryland announced…
On Dec. 23, 2021, Novavax and SK bioscience announced the expansion of the companies’ collaboration and license agreements…
On Dec. 22, 2021, Novavax announced initial data evaluating the immune response of its COVID-19 vaccine, NVX-CoV2373, against…
On Dec. 21, 2021, Novavax announced that the first booster doses of NVX-CoV2373, the company’s recombinant nanoparticle protein-based…
On Dec. 20, 2021, Novavax announced that the World Health Organization (WHO) had granted a second Emergency Use…
On Dec. 20, 2021, Novavax announced that the European Commission (EC) had granted Novavax conditional marketing authorization (CMA)…
On Dec. 17, 2021, Novavax and SK bioscience announced that the World Health Organization (WHO) had granted Emergency…
On Dec. 15, 2021, Novavax announced the submission of a New Drug Application to the Ministry of Health,…
On Dec. 13, 2021, Novavax announced that it had submitted a regulatory filing to the Ministry of Health…
On Nov. 24, 2021, Novavax announced its submission to the Singapore Health Sciences Authority for interim authorization of…
On Nov. 17, 2021, Novavax and and Serum Institute of India announced that the Philippine Food and Drug…
On Nov. 17, 2021, Novavax announced that the European Medicines Agency (EMA) had begun its evaluation of an…
On Nov. 17, 2021, Zosano Pharma announced that the Philippine Food and Drug Administration had granted emergency use…
On Nov. 17, 2021, scientists at the Centers for Disease Control and Prevention (CDC) announced they were collaborating…
On Nov. 15, 2021, Novavax and SK bioscience announced submission of a Biologics License Application (BLA) for Novavax’…
On Nov. 15, 2021, a large, long-term study of the impacts of COVID-19 on children announced it had…
On Nov. 4, 2021, Novavax announced the completion of its rolling submission to the World Health Organization (WHO)…
On Nov. 3, 2021, Novavax announced the company had filed for provisional approval of the vaccine to the…
On Nov. 1, 2021, Novavax announced the completion of its rolling submission to Health Canada for authorization of…
On Nov. 1, 2021, Novavax and Serum Institute of India announced that the National Agency of Drug and…
On Oct. 29, 2021, Novavax announced the completion of its rolling submission to the Therapeutic Goods Administration (TGA)…
On Oct. 27, 2021, Novavax announced the completion of its rolling regulatory submission to the U.K. Medicines and…
On Sept. 23, 2021, Novavax with its partner, Serum Institute of India announced a regulatory submission to the…
On Sept. 23, 2021, Novavax announced publication of complete results from a pivotal Phase 3 clinical trial of…
On Sept. 16, 2021, Novavax announced its participation in a newly expanded Phase 2 clinical trial called Comparing…
On Sept. 8, 2021, Novavax announced enrollment of the first participants in a Phase 1/2 study to evaluate…
On Sept. 7, 2021, Takeda Pharmaceutical announced the Government of Japan’s Ministry of Health, Labour and Welfare purchase…